Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Toby L. Simon"'
Autor:
Amy E, Schmidt, Peter, Vogel, Carrie A, Chastain, Thomas, Barnes, Nathan J, Roth, Toby L, Simon
Publikováno v:
Journal of Clinical Apheresis. 37:449-459
COVID-19 convalescent plasma (CCP) was approved under emergency authorization to treat critically ill patients with COVID-19 in the United States in 2020. We explored the demographics of donors contributing plasma for a hyperimmune, plasma-derived th
Autor:
Bryan R. Spencer, Toby L. Simon
Publikováno v:
Rossi's Principles of Transfusion Medicine. :56-64
Publikováno v:
Rossi's Principles of Transfusion Medicine. :25-36
Publikováno v:
Journal of Clinical Apheresis.
Publikováno v:
Journal of Clinical Apheresis. 37:31-39
BACKGROUND Plasma contains many important proteins of therapeutic interest including albumin, clotting factors, and antibodies. Source plasma (SP) is in great demand particularly due to a shortage of immunoglobulin. To better understand how to increa
Autor:
Kelley Hyatt, Rick Alexander, Mathias Schemmerer, Carol Kralicek, Eleonora Widmer, Jon Knowles, Nathan J. Roth, Denis Klochkov, Martin Wälti, Jürgen J. Wenzel, Keith Bycholski, Björn Keiner, Stephanie Schoch, Toby L. Simon
Publikováno v:
Emerging Infectious Diseases, Vol 27, Iss 11, Pp 2818-2824 (2021)
Emerging Infectious Diseases
Emerging Infectious Diseases
The United States is currently affected by widespread hepatitis A virus (HAV) outbreaks. We investigated HAV incidence rates among source plasma donors in the United States since 2016. Serial donations from HAV-positive frequent donors were analyzed
Autor:
Toby L. Simon, George B. Schreiber, Guang Song, Mark Becker, James Lenart, Janet Hershman, Michelle Fransen
Publikováno v:
Transfusion. 61:2941-2957
BACKGROUND Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
Autor:
Jonathan Knowles, Keith Bycholski, Peter Fitzgerald, Othmar Zenker, Toby L. Simon, Mirjam Kühne, Connie Farrar
Publikováno v:
Transfusion. 58:3065-3071
Background To ensure that immunoglobulin (Ig) products have adequate functional antibody, the US Food and Drug Administration (FDA) requires that Ig lots contain minimum levels of measles neutralizing antibody; the current minimum is 0.48 x US Refere
Autor:
Aaron Hahn, Uwe Kalina, Thomas Hauser, Daniel Filchtinski, Nathan J. Roth, Patrick Schuetz, Thomas W. Barnes, Michelle R. Williams, Johannes Schulte-Pelkum, Christina Kober, Laura Steller, Robin Jenness, Toby L. Simon, Sandro Manni
Publikováno v:
Clinical Immunology Society
Clinical Immunology (Orlando, Fla.)
Clinical Immunology (Orlando, Fla.)
Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunologica
Autor:
Toby L. Simon, Alphonse Hubsch, Amgad Shebl, Christopher Wallenhorst, Ami Patel, Carlos Martinez
Publikováno v:
Transfusion
BACKGROUND Intravenous immunoglobulins (IVIG) are derived from large human plasma pools. IVIG‐associated hemolytic anemia (HA) is a known class effect, likely attributed to dose‐dependent passive transfer of anti‐A/B isoagglutinins. Two isoaggl